AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Net-Income-Including-Non-Controlling-Interests" stands at 9.45 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 03/31/2012.
AstraZeneca PLC's third quarter result of 2.54 Billion USD for the item "Net Income Including Non Controlling Interests" represents an increase of 0.14 percent compared to it's second quarter result.
Also, AstraZeneca PLC's third quarter result of 2.54 Billion USD for the item "Net Income Including Non Controlling Interests" represents an increase of 70.49 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 9.45 Billion USD for the item "Net Income Including Non Controlling Interests" represents an increase of 12.48 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 2.90 Billion United States Dollars compared to the value the year prior.
The 1 year change is 2.90 Billion United States Dollars.
The 3 year change is 7.48 Billion United States Dollars.
The 5 year change is 7.06 Billion United States Dollars.
The 10 year change is 7.75 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income Including Non Controlling Interests | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Income Including Non Controlling Interests | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Income Including Non Controlling Interests | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income Including Non Controlling Interests | 317,433,206,677.55 |
![]() | Novartis AG - Net Income Including Non Controlling Interests | 255,096,620,580.91 |